Patents by Inventor Michael Patrick Dillon

Michael Patrick Dillon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12115163
    Abstract: Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatment of a variety of cancers, including solid tumors. The combination product is useful for the treatment of any number of MAT2A-associated and/or PRMT-associated diseases.
    Type: Grant
    Filed: January 5, 2024
    Date of Patent: October 15, 2024
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Michael Patrick Dillon, Claire L. Neilan, Marcus Michael Fischer, Kimberline Yang Gerrick
  • Publication number: 20240269143
    Abstract: Provided herein is a combination therapy and methods of using such combination therapy to treat diseases or disorders associated with MAT2A and/or Type I PRMT.
    Type: Application
    Filed: June 1, 2022
    Publication date: August 15, 2024
    Inventors: Michael Patrick DILLON, Marcus Michael FISCHER, Kimberline Yang GERRICK, Jenny Laraio, Helai Mohammad, Kimberly Smitheman
  • Publication number: 20240173326
    Abstract: Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatment of a variety of cancers, including solid tumors. The combination product is useful for the treatment of any number of MAT2A-associated and/or PRMT-associated diseases.
    Type: Application
    Filed: January 5, 2024
    Publication date: May 30, 2024
    Inventors: Michael Patrick DILLON, Claire L. NEILAN, Marcus Michael FISCHER, Kimberline Yang GERRICK
  • Publication number: 20240158356
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: April 27, 2023
    Publication date: May 16, 2024
    Applicant: Roche Palo Alto LLC
    Inventors: CHRIS ALLEN BROKA, DAVID SCOTT CARTER, MICHAEL PATRICK DILLON, RONALD CHARLES HAWLEY, ALAM JAHANGIR, CLARA JEOU JEN LIN, DANIEL WARREN PARISH
  • Publication number: 20240108626
    Abstract: Provided herein is a combination product comprising a methionine adenosyltransferase II alpha (MAT2A) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The combination product is useful for the treatment of a variety of cancers, including solid tumors. The combination product is useful for the treatment of any number of MAT2A-associated and/or PRMT-associated diseases.
    Type: Application
    Filed: November 3, 2023
    Publication date: April 4, 2024
    Inventors: Michael Patrick DILLON, Claire L. NEILAN, Marcus Michael FISCHER, Kimberline Yang GERRICK
  • Publication number: 20230303556
    Abstract: Provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof. The provided compounds are useful Poly ADP-ribose glycohydrolase (PARG) inhibitors. Additional utilities and advantages are described herein.
    Type: Application
    Filed: March 22, 2023
    Publication date: September 28, 2023
    Inventors: Paul A. BARSANTI, Michael Patrick DILLON, Firoz Ali JAIPURI, Ying-Zi XU, Xin LINGHU, Monah ABED
  • Publication number: 20230303510
    Abstract: The present invention relates to methods for treating bacterial infections caused by or Provided and set forth herein are certain cyclized acetamido derivatives that are DNA Polymerase Theta (Pol?) inhibitors of Formula (I) and Formula II. Also, provided are pharmaceutical compositions comprising such compounds, and methods of treating diseases treatable by inhibition of Pol? such as cancer, including homologous recombination (HR) deficient cancers, using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: July 28, 2021
    Publication date: September 28, 2023
    Inventors: Hilary Plake BECK, Michael Patrick DILLON, Brian Thomas JONES, Luisruben Padilla MARTINEZ
  • Publication number: 20230100975
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: March 22, 2022
    Publication date: March 30, 2023
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Patent number: 11584755
    Abstract: Compounds are provided having Formula (I): wherein R, R1, Cyc and A have the meanings provided herein. The compounds have utility in the treatment of diseases, either alone or in combination with other agents.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: February 21, 2023
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Hilary Plake Beck, Leah Brigit Cleary, Michael Patrick Dillon, Marcos Gonzalez-Lopez, Luis Ruben P. Martinez, James Clifford Sutton, Jr.
  • Publication number: 20230039955
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2e and R2d have the meanings provided in the specification.
    Type: Application
    Filed: June 29, 2022
    Publication date: February 9, 2023
    Inventors: Muzaffar ALAM, Hilary Plake BECK, Michael Patrick DILLON, Marcos GONZALEZ-LOPEZ, James Clifford SUTTON, JR.
  • Patent number: 11548867
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: January 10, 2023
    Assignee: IDEA YA BIOSCIENCES, INC.
    Inventors: Muzaffar Alam, Hilary Plake Beck, Michael Patrick Dillon, Marcos Gonzalez-Lopez, Alice Chen Rico, James Clifford Sutton, Jr.
  • Publication number: 20220389003
    Abstract: Provided herein are compounds having the formula: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, Ar, X1, X2, and ring B have the meanings as provided herein. The provided compounds are useful Poly ADP-ribose glycohydrolase (PARG) inhibitors.
    Type: Application
    Filed: September 18, 2020
    Publication date: December 8, 2022
    Inventors: James Clifford SUTTON, Jr., Michael Patrick Dillon
  • Publication number: 20220340875
    Abstract: Provided are methods for expanding stem cells and/or lineage committed progenitor cells, such as hematopoietic stems cells and/or lineage committed progenitor cells, at least in part, by using compounds that antagonize AhR. The compounds are represented by formulae: wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification. Also provided are compositions comprising stem cells and/or lineage committed progenitor cells expanded by methods disclosed herein and methods for the treatment of diseases treatable by same.
    Type: Application
    Filed: July 18, 2019
    Publication date: October 27, 2022
    Inventors: Muzaffar ALAM, Fred ASWAD, Hilary Plake BECK, Michael Patrick DILLON, Marcos GONZALEZ-LOPEZ, Yujiro HATA, Alice Chen RICO, James Clifford SUTTON, Jr.
  • Patent number: 11407764
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided in the specification.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: August 9, 2022
    Assignee: IDEAYA BIOSCIENCES, INC.
    Inventors: Muzaffar Alam, Hilary Plake Beck, Michael Patrick Dillon, Marcos Gonzalez-Lopez, James Clifford Sutton, Jr.
  • Publication number: 20220227780
    Abstract: Compounds are provided having Formula (I): wherein R, R1, Cyc and A have the meanings provided herein. The compounds have utility in the treatment of diseases, either alone or in combination with other agents.
    Type: Application
    Filed: September 25, 2018
    Publication date: July 21, 2022
    Inventors: Hilary Plake BECK, Leah Brigit CLEARY, Michael Patrick DILLON, Marcos GONZALES-LOPEZ, Luis Ruben P. MARTINEZ, James Clifford SUTTON
  • Publication number: 20210254006
    Abstract: Provided are methods for expanding stem cells and/or lineage committed progenitor cells, at least in part, by using lactam compounds that antagonize AhR. The compounds are represented by formula (I): wherein the letters and symbols X1, X2, Z, R1b, R1c, R1d, R1e, R2a, R2b, R2c and R2d have the meanings provided below. Also provided are compositions comprising stem cells and/or lineage committed progenitor cells expanded by methods disclosed herein and methods for the treatment of diseases treatable by same.
    Type: Application
    Filed: June 5, 2019
    Publication date: August 19, 2021
    Inventors: Muzaffar ALAM, Fred ASWAD, Hilary Plake BECK, Michael Patrick DILLON, Marcos GONZALEZ-LOPEZ, Yujiro HATA, James Clifford SUTTON, Jr.
  • Publication number: 20210155606
    Abstract: The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Application
    Filed: February 8, 2021
    Publication date: May 27, 2021
    Inventors: Luca ARISTA, Sreehari BABU, Jianwei BIAN, Kai CUI, Michael Patrick DILLON, Rene LATTMANN, Jialiang LI, Lv LIAO, Dimitrios LIZOS, Rita RAMOS, Nikolaus Johannes STIEFL, Thomas ULLRICH, Peggy USSELMANN, Xiaoyang WANG, Liladhar Murlidhar WAYKOLE, Sven WEILER, Yubo ZHANG, Yizong ZHOU, Tingying ZHU
  • Publication number: 20210115016
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.
    Type: Application
    Filed: July 18, 2018
    Publication date: April 22, 2021
    Inventors: Muzaffar ALAM, Hilary Plake BECK, Michael Patrick DILLON, Marcos GONZALEZ-LOPEZ, Alice Chen RICO, James Clifford SUTTON, Jr.
  • Patent number: 10947218
    Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: March 16, 2021
    Assignee: NOVARTIS AG
    Inventors: Luca Arista, Sreehari Babu, Jianwei Bian, Kai Cui, Michael Patrick Dillon, Rene Lattmann, Jialiang Li, Lv Liao, Dimitrios Lizos, Rita Ramos, Nikolaus Johannes Stiefl, Thomas Ullrich, Peggy Usselmann, Xiaoyang Wang, Liladhar Murlidhar Waykole, Sven Weiler, Yubo Zhang, Yizong Zhou, Tingying Zhu
  • Publication number: 20210009531
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: September 25, 2020
    Publication date: January 14, 2021
    Applicant: Roche Palo Alto LLC
    Inventors: CHRIS ALLEN BROKA, DAVID SCOTT CARTER, MICHAEL PATRICK DILLON, RONALD CHARLES HAWLEY, ALAM JAHANGIR, CLARA JEOU JEN LIN, DANIEL WARREN PARISH